01:48 AM EDT, 05/07/2026 (MT Newswires) -- BMO Capital Markets raised its price target for Novo Nordisk's (NOVO-B.CO) shares on the New York Stock Exchange to $45 from $36, citing increased expectations for the launch of the Wegovy pill and higher 2026 guidance.

The Danish drugmaker's first-quarter results on Wednesday showed that 2 million prescriptions for the oral weight-loss drug were filled year to date, exceeding uptake expectations.

Given the strong incretin performance, the research firm lifted its estimates for Ozempic, Wegovy, and the Wegovy pill by 5%, 2%, and 29%, respectively, for 2026. The projection for total adjusted revenue was increased by 2%, while that for adjusted EPS was cut by 4%.

"Today's print and modest guidance raise could help improve investor confidence as Novo works to recover from prior strategic mishaps,"analysts said. "Still we need to see consistent execution and a clear strategy before we can get fully comfortable with the story. A strong 1Q signals the company is making progress, but a modest guidance raise reflects continued conservatism over the balance of 2026."The stock is rated market perform.